title: Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases.
abstract: Hepatic arterial floxuridine (HAI) in 35 patients with systemic fluorouracil/folinic acid-resistant colorectal liver metastases achieved a 14% partial response and 26% disease stabilization rate, with a median response duration of 7 months from onset of HAI.
authors.affiliation: Department of Gastrointestinal Surgery, Imperial College School of Medicine, Chelsea and Westminster Hospital, London, UK.
authors.forename: C
authors.initials: C
authors.lastname: Fordy
authors.forename: C
authors.initials: C
authors.lastname: Glover
authors.forename: M M
authors.initials: MM
authors.lastname: Davies
authors.forename: T G
authors.initials: TG
authors.lastname: Allen-Mersh
mesh_terms: D015179:Colorectal Neoplasms / Q000473:pathology*; D019008:Drug Resistance, Neoplasm; D005467:Floxuridine / Q000008:administration & dosage* / Q000009:adverse effects; D005472:Fluorouracil / Q000627:therapeutic use*; D006499:Hepatic Artery; D006801:Humans; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D011788:Quality of Life; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D005467:Floxuridine; D005472:Fluorouracil